Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety and pharmacokinetic study of WCK 4282 (cefepime + tazobactam) in healthy volunteers
NL-OMON43462Phase 1Active, not recruiting
- Sponsor
- Wockhardt
- Start
- Jan 2016
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cefepime and tazobactam in bacterial disease (5 arms), sponsored by Wockhardt. Primary endpoints: Safety, Tolerability and 1 more. Started Jan 2016; status: active, not recruiting.
02
Drugs
cefepimetazobactam
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON43462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43462.